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Introduction: Fallopian tube carcinoma is a rare gynecological malignancy with low accuracy detection
preoperatively. The symptoms are unspecific and imaging can be misleading. Since it was first described in
1847, there have been only a little over 2000 case reports.
Case presentation: This case report describes a 66-year-old Caucasian woman who presented with progressive
diffuse abdominal pain, without other symptoms. After abdominopelvic magnetic resonance imaging, she was sent to
the Portuguese Oncology Institute of Oporto with the suspicion of peritoneal carcinomatosis of unknown primary
tumor. Due to a pelvic palpable mass (calcified giant uterine fibroid) she was directed to the Gynecology team. Surgery
was performed and a large mass in her upper abdomen was identified. The extemporary examination revealed a
high-grade adenocarcinoma. During surgery a small change of color and consistency of her left fallopian tube was
noted and unilateral adnexectomy was performed. After pathologic and immunohistochemistry tests, the diagnosis of
fallopian tube carcinoma with peritoneal dissemination was made.
Conclusions: This case is very unique in the way that a small primary fallopian tube carcinoma was able to
disseminate to the upper abdominal quadrant with little pelvic dissemination. The symptoms and imaging were
unspecific. Although a rare occurrence, we should not forget fallopian tube carcinoma in the differential diagnosis of
peritoneal carcinomatosis, even in the absence of Latzke’s triad.
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Primary fallopian tube carcinoma (PFTC) is a rare
gynecological malignancy that accounts for 0.14 to 1.8%
of all gynecological cancers [1]. It was first described in
1847 by Renaud and a little over 2000 cases have been
reported to date. Its prevalence is believed to be higher
than reported [2] because of its histological pattern
(similar to epithelial ovarian cancer) and late stage
diagnosis presenting with extensive pelvic dissemination
(the ovary being considered the primary tumor). PFTC
usually presents in the sixth decade of life [1] and the
predisposing factors are not well determined, although
nulliparity, infertility and inflammatory pelvic disease may
have an influence [3]. The presence of BRCA genetic* Correspondence: anameneses@iol.pt
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reproduction in any medium, provided the ormutation confers an augmented risk of developing PFTC.
Some suggest that in all PFTC cases encountered in their
series 16% have BRCA mutations [4]. Symptoms include
profuse vaginal discharge, abnormal vaginal bleeding,
pelvic or abdominal pain (usually colicky pain due to tube
distension) and a pelvic and/or abdominal mass can be
palpable [5]. Latzke’s triad, which comprises watery vaginal
discharge, vaginal bleeding with pelvic and/or abdominal
pain, presents in only 15% of cases [6]. Preoperative
diagnosis is difficult and imaging can be misleading
because it may not identify the primary tumor. Pelvic
ultrasound can be used to assess “sausage-like” images,
related to tubal distension, as well as vascular abnormalities
using Doppler ultrasound [7]. Depending on the series, there
is a 3 to 4% rate of preoperative diagnosis [8]. Diagnosis is
usually histological and has to meet specific criteria [9].
Tumor dissemination in cases of PFTC is preferentially
transperitoneal and lymphatic [1] which can explain the
higher incidence (in comparison to the ovary) of distant and
retroperitoneal metastases [10]. Staging, surgical treatmentLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominopelvic magnetic resonance imaging.
Axial T2-weighted image. Heterogeneous soft-tissue thickening of the
greater omentum (“omental cake”) (arrow). Moderate ascites (arrowhead).
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ciples of epithelial ovarian cancers [11,12]. Prognosis
is highly dependent of stage at diagnosis. A 5-year
survival can range between 50 and 60% (stage II) and
10 and 20% (stages III and IV) [1]. Other series report
different survival rates, but use more aggressive chemo-
therapeutic protocols. There are some unfavorable prog-
nostic factors besides stage: age above 50-years old [13],
tubal muscular layer (>50%) and/or serosal invasion [1],
less optimal cytoreduction [12] and histological poor
differentiation [14]. Surprisingly, primary tumor size does
not affect prognosis [1].
Case presentation
This case report presents a 66-year-old Caucasian female
housekeeper. Her background includes squamous
carcinoma of the nose treated with surgery (14 years ago),
hypertension and appendectomy (at a young age). She was
nulliparous and had no previous known gynecological
problems (menarche and menopause at normal ages, no
combined hormonal contraceptives or hormonal replace-
ment therapy). Her only symptom was diffuse abdominal
pain, more intense on the flanks, progressing for 3 months
and with increasing intensity. The family doctor requested
a computed tomography scan that suggested peritoneal
carcinomatosis, moderate ascites, with no reference to the
primary tumor site. When further examined, a complete
and thorough examination showed:
1. No vaginal discharge, endocervical polyp
(no dysplasia) and normal cervical-vaginal cytology.
2. Blood work: elevation of CA-125 (515UI/mL),
CA-19.9 and carcinoembryonic antigen within
normal range, hepatic enzymes slightly elevated.
3. Diagnostic paracentesis: no malignant cells.
4. Gastrointestinal tract study: normal upper and
lower endoscopy.
5. Abdominopelvic magnetic resonance imaging (MRI):
moderate ascites, peritoneal thickening around
transverse mesocolon and omental involvement
(“omental cake”) (Figure 1) and a large, calcified
uterine fibroid.
The patient’s case was reviewed by the Gynecology
team at the Portuguese Institute of Oncology of Oporto and
an exploratory laparotomy was decided. The intra-operatory
findings showed diffuse parietal peritoneal implants
(pelvic and abdominal) with a voluminous mass involving
her epiploon, from the hepatic hilum to the splenic hilum,
invading the great gastric curvature. An anterior abdominal
wall implant was removed and sent for extemporary
examination which revealed high-grade adenocarcinoma.
Ascitic fluid was collected; atypical gastrectomy, omentect-
omy and myomectomy were performed. When reviewingthe adnexial area, a small dilation and purple color were
noticed on her left fallopian tube. The surgery was
completed with left adnexectomy. Macroscopic residual
disease (>2cm) was present at the end of surgery. During
the postoperatory period, a positron emission tomography
scan revealed multiple ganglion metastases with several
small implants on her pelvic and abdominal cavities
(Figure 2). The pathology report showed infiltrative
serous adenocarcinoma of epiploon and gastric curvature
(papillary pattern Figures 3A and 3B), invading the gastric
muscular layer, but not the mucosa. When analyzing her
left fallopian tube, the same adenocarcinoma type was
found in the lumen (9mm in size) but it had not invaded
the muscular layer (Additional file 1: Figure S1 – A, B).
Intraepithelial neoplastic segments were found in other
parts of the tubal mucosa. Her left ovary was normal.
Immunohistochemical analysis, using p53 and Ki-67 index,
matched the tumor tissue in the abdominal implants with
the tumor in her fallopian tube (Additional file 2: Figure S2),
which led us to reach the conclusion of PFTC (higher
differentiation of the tubal neoplasia and presence of
intraepithelial neoplastic areas). The patient was then
enrolled for six cycles of paclitaxel with carboplatin
without complications.
Discussion
The symptomatic presentation was very unspecific and
the pelvic imaging found only a large uterine fibroid.
Optimal cytoreduction was not possible and hysterectomy
with right adnexectomy was not considered because the
primary tumor appeared to be gastric or peritoneal and
residual upper abdominal tumor volume was high. The
diagnosis of a PFTC was made with anatomical-pathological
findings and immunohistochemistry tests, although the
Figure 2 Positron emission tomography scan. Multiple ganglion metastases with several small implants on the pelvic and abdominal cavities
(slides 1 and 3 – coronal section; slide 5 – sagittal section).
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CA-125 measurement started at 518.5UI/mL, after surgery
it was 59.94UI/mL and after two chemotherapy cycles the
value was normal (13.13UI/mL).
Pelvic MRI is not totally specific for adnexal evaluation
[15] and pelvic ultrasound with color Doppler could be
helpful in better characterization of the pelvic organs [5].
The higher tubal neoplasia differentiation, the invasion
only of her stomach’s outer layers, the presence of
intraepithelial tubal neoplastic areas and the complete
response to chemotherapy (imaging and the CA-125
descent), favors the diagnosis of PTFC with secondary
peritoneal involvement. Extensive metastasis in the
upper abdomen without PTFC muscle and serous coats
breach is possible due to the exfoliation of malignant
cells into the peritoneal fluid, followed by the natural
flow of peritoneal fluid in the peritoneal cavity, which
can take the metastasis to the upper abdomen.
Conclusions
PFTC is a rare entity that poses diagnostic challenges.
Symptoms, imaging and even pathological findings are
not straight forward. In this case report we found a
small PFTC (9mm) with extensive upper abdominal
dissemination. This kind of presentation is unusual,Figure 3 Primary fallopian tube carcinoma. Hematoxylin and eosin stain
(A); papillary serous adenocarcinoma with solid areas (B); moderate nucleaalthough it presented at a late stage (International
Federation of Gynecology and Obstetrics III) as do most
PFTCs. The staging and adjuvant therapy in PFTC is
similar to that of epithelial ovarian cancer and primary
peritoneal cancer [11]. The apparent defiance of serous
carcinomas to conform to the adenoma-carcinoma models
is probably linked to the propensity of this tumor to spread
early in its course. The dissemination process seems to be
independent of initial primary tumor size and transperito-
neal and lymphatic spread are more relevant [1]. In past
years, peritoneal serous carcinogenic sequence has been
reviewed in the light of new findings. Tubal fimbriae
became the focus of the studies and the conclusions from
these works are that the initial modified criteria by Hu
et al. [16] for the diagnosis of PTFC detects only a portion
of PTFCs and that the fallopian tube is a major site of
origin for pelvic serous cancer irrespective of BRCA status.
Other recent studies from several cancer institutes
have identified a number of promising biomarkers
including HE4, mesothelin, and kallikreins. It would be
possible to look for membrane and secreted proteins
that distinguish the normal fallopian tube epithelium
from its malignant counterpart. This is an essential
step in the development of diagnostic and prognostic
biomarkers for this disease.showing total inclusion of tubal neoplasia growing inside the lumen
r atypia (C).
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for publication of this case report and accompanying
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Additional files
Additional file 1: Figure S1. Epiploon and gastric curvature.
Hematoxylin and eosin stain showing infiltrative serous adenocarcinoma
with papillary pattern (A). Severe nuclear atypia (B).
Additional file 2: Figure S2. Immunohistochemical analysis.
Immunohistochemistry stains showing intense and diffuse p53 signature
on the affected mucosa (Fig. A) and high proliferative Ki67 index (Fig. B).
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